TY - JOUR
T1 - Osteosarcoma of the pelvis
T2 - Experience of the Cooperative Osteosarcoma Study Group
AU - Ozaki, Toshifumi
AU - Flege, Silke
AU - Kevric, Matthias
AU - Lindner, Norbert
AU - Maas, Rainer
AU - Delling, Günter
AU - Schwarz, Rudolf
AU - Von Hochstetter, Arthur R.
AU - Salzer-Kuntschik, Mechthild
AU - Berdel, Wolfgang E.
AU - Jürgens, Heribert
AU - Exner, G. Ulrich
AU - Reichardt, Peter
AU - Mayer-Steinacker, Regine
AU - Ewerbeck, Volker
AU - Kotz, Rainer
AU - Winkelmann, Winfried
AU - Bielack, Stefan S.
PY - 2003/1/15
Y1 - 2003/1/15
N2 - Purpose: To define patients and tumor characteristics as well as therapy results, patients with pelvic osteosarcoma who were registered in the Cooperative Osteosarcoma Study Group (COSS) were analyzed. Patients and Methods: Sixty-seven patients with a high-grade pelvic osteosarcoma were eligible for this analysis. Fifteen patients had primary metastases. All patients received chemotherapy according to COSS protocols. Thirty-eight patients underwent limb-sparing surgery, 12 patients underwent hemipelvectomy, and 17 patients did not undergo definitive surgery. Eleven patients received irradiation to the primary tumor site: four postoperatively and seven as the only form of local therapy. Results: Local failure occurred in 47 of all 67 patients (70%) and in 31 of 50 patients (62%) who underwent definitive surgery. Five-year overall survival (OS) and progression-free survival rates were 27% and 19%, respectively. Large tumor size (P = .0137), primary metastases (P = .0001), and no or intralesional surgery (P < .0001) were poor prognostic factors. In 30 patients with no or intralesional surgery, 11 patients with radiotherapy had better OS than 19 patients without radiotherapy (P = .0033). Among the variables, primary metastasis, large tumor, no or intralesional surgery, no radiotherapy, existence of primary metastasis (relative risk [RR] = 3.456; P = .0009), surgical margin (intralesional or no surgical excision; RR = 5.619; P < .0001), and no radiotherapy (RR = 4.196; P = .0059) were independent poor prognostic factors. Conclusion: An operative approach with wide or marginal margins improves local control and OS. If the surgical margin is intralesional or excision is impossible, additional radiotherapy has a positive influence on prognosis.
AB - Purpose: To define patients and tumor characteristics as well as therapy results, patients with pelvic osteosarcoma who were registered in the Cooperative Osteosarcoma Study Group (COSS) were analyzed. Patients and Methods: Sixty-seven patients with a high-grade pelvic osteosarcoma were eligible for this analysis. Fifteen patients had primary metastases. All patients received chemotherapy according to COSS protocols. Thirty-eight patients underwent limb-sparing surgery, 12 patients underwent hemipelvectomy, and 17 patients did not undergo definitive surgery. Eleven patients received irradiation to the primary tumor site: four postoperatively and seven as the only form of local therapy. Results: Local failure occurred in 47 of all 67 patients (70%) and in 31 of 50 patients (62%) who underwent definitive surgery. Five-year overall survival (OS) and progression-free survival rates were 27% and 19%, respectively. Large tumor size (P = .0137), primary metastases (P = .0001), and no or intralesional surgery (P < .0001) were poor prognostic factors. In 30 patients with no or intralesional surgery, 11 patients with radiotherapy had better OS than 19 patients without radiotherapy (P = .0033). Among the variables, primary metastasis, large tumor, no or intralesional surgery, no radiotherapy, existence of primary metastasis (relative risk [RR] = 3.456; P = .0009), surgical margin (intralesional or no surgical excision; RR = 5.619; P < .0001), and no radiotherapy (RR = 4.196; P = .0059) were independent poor prognostic factors. Conclusion: An operative approach with wide or marginal margins improves local control and OS. If the surgical margin is intralesional or excision is impossible, additional radiotherapy has a positive influence on prognosis.
UR - http://www.scopus.com/inward/record.url?scp=20244363030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20244363030&partnerID=8YFLogxK
U2 - 10.1200/JCO.2003.01.142
DO - 10.1200/JCO.2003.01.142
M3 - Article
C2 - 12525527
AN - SCOPUS:20244363030
SN - 0732-183X
VL - 21
SP - 334
EP - 341
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 2
ER -